Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tritanrix-HepB/Hib-MenAC vs Tritanrix-HepB/Hiberix Immunogenicity Study in Infants
NCT00317122Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2004
- Primary completion
- Jul 2005
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Tritanrix-HepB/Hib-MenAC in diphtheria, Tetanus, pertussis, hepatitis B (HBV), Haemophilus influenzae type b infection (Hib), sponsored by GSK. Started Oct 2004; status: completed.
02
Drugs
Tritanrix-HepB/Hib-MenAC
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00317122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317122.